The DOI matches its Crossref record; 82 of the 82 references it cites were found in a registry or an index.
The selectivity of protein kinase inhibitors: a further update
Open accessAbstract
The specificities of 65 compounds reported to be relatively specific inhibitors of protein kinases have been profiled against a panel of 70–80 protein kinases. On the basis of this information, the effects of compounds that we have studied in cells and other data in the literature, we recommend the use of the following small-molecule inhibitors: SB 203580/SB202190 and BIRB 0796 to be used in parallel to assess the physiological roles of p38 MAPK (mitogen-activated protein kinase) isoforms, PI-103 and wortmannin to be used in parallel to inhibit phosphatidylinositol (phosphoinositide) 3-kinases, PP1 or PP2 to be used in parallel with Src-I1 (Src inhibitor-1) to inhibit Src family members; PD 184352 or PD 0325901 to inhibit MKK1 (MAPK kinase-1) or MKK1 plus MKK5, Akt-I-1/2 to inhibit the activation of PKB (protein kinase B/Akt), rapamycin to inhibit TORC1 [mTOR (mammalian target of rapamycin)–raptor (regulatory associated protein of mTOR) complex], CT 99021 to inhibit GSK3 (glycogen synthase kinase 3), BI-D1870 and SL0101 or FMK (fluoromethylketone) to be used in parallel to inhibit RSK (ribosomal S6 kinase), D4476 to inhibit CK1 (casein kinase 1), VX680 to inhibit Aurora kinases, and roscovitine as a pan-CDK (cyclin-dependent kinase) inhibitor. We have also identified harmine as a potent and specific inhibitor of DYRK1A (dual-specificity tyrosine-phosphorylated and -regulated kinase 1A) in vitro. The results have further emphasized the need for considerable caution in using small-molecule inhibitors of protein kinases to assess the physiological roles of these enzymes. Despite being used widely, many of the compounds that we analysed were too non-specific for useful conclusions to be made, other than to exclude the involvement of particular protein kinases in cellular processes.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Meijer, L., Nelson, D. J., Riazanski, V., Gabdoulkhakova, A. G., Hery-Arnaud, G., Le Berre, R., Loaëc, N., Oumata, N., Galons, H., Nowak, E., et al. (2016) · Journal of Innate Immunity · doi:10.1159/000444256 · Cited by 4,992
Wilhelm, S. M., Carter, C., Tang, L., Wilkie, D., McNabola, A., Rong, H., Chen, C., Zhang, X., Vincent, P., McHugh, M., et al. (2004) · Cancer Research · doi:10.1158/0008-5472.can-04-1443 · Cited by 4,017
Alessi, D. R., Cuenda, A., Cohen, P., Dudley, D. T., & Saltiel, A. R. (1995) · Journal of Biological Chemistry · doi:10.1074/jbc.270.46.27489 · Cited by 3,393
Self-citationWatterson, K. R., Bestow, D., Gallagher, J., Hamilton, D. L., Ashford, F. B., Meakin, P. J., & Ashford, M. L. J. (2013) · Neurosignals · doi:10.1159/000334144 · Cited by 3,389
Specificity and mechanism of action of some commonly used protein kinase inhibitors
DAVIES, S. P., REDDY, H., CAIVANO, M., & COHEN, P. (2000) · Biochemical Journal · doi:10.1042/bj3510095 · Cited by 3,132
Self-citationIdentification of a Novel Inhibitor of Mitogen-activated Protein Kinase Kinase
Favata, M. F., Horiuchi, K. Y., Manos, E. J., Daulerio, A. J., Stradley, D. A., Feeser, W. S., Van Dyk, D. E., Pitts, W. J., Earl, R. A., Hobbs, F., et al. (1998) · Journal of Biological Chemistry · doi:10.1074/jbc.273.29.18623 · Cited by 3,015
Regulation of Myosin Phosphatase by Rho and Rho-Associated Kinase (Rho-Kinase)
Kimura, K., Ito, M., Amano, M., Chihara, K., Fukata, Y., Nakafuku, M., Yamamori, B., Feng, J., Nakano, T., Okawa, K., et al. (1996) · Science · doi:10.1126/science.273.5272.245 · Cited by 2,884
Calcium sensitization of smooth muscle mediated by a Rho-associated protein kinase in hypertension
Uehata, M., Ishizaki, T., Satoh, H., Ono, T., Kawahara, T., Morishita, T., Tamakawa, H., Yamagami, K., Inui, J., Maekawa, M., et al. (1997) · Nature · doi:10.1038/40187 · Cited by 2,859
Hidaka, H., Inagaki, M., Kawamoto, S., & Sasaki, Y. (1984) · Biochemistry · doi:10.1021/bi00316a032 · Cited by 2,687
(1995) · FEBS Letters · doi:10.1016/0014-5793(95)00357-f · Cited by 2,086
Targets for Cell Cycle Arrest by the Immunosuppressant Rapamycin in Yeast
Heitman, J., Movva, N. R., & Hall, M. N. (1991) · Science · doi:10.1126/science.1715094 · Cited by 2,006
Discovery of a Novel, Potent, and Src Family-selective Tyrosine Kinase Inhibitor
Hanke, J. H., Gardner, J. P., Dow, R. L., Changelian, P. S., Brissette, W. H., Weringer, E. J., Pollok, B. A., & Connelly, P. A. (1996) · Journal of Biological Chemistry · doi:10.1074/jbc.271.2.695 · Cited by 1,939
Structural Mechanism for STI-571 Inhibition of Abelson Tyrosine Kinase
Schindler, T., Bornmann, W., Pellicena, P., Miller, W. T., Clarkson, B., & Kuriyan, J. (2000) · Science · doi:10.1126/science.289.5486.1938 · Cited by 1,780
Hawley, S. A., Pan, D. A., Mustard, K. J., Ross, L., Bain, J., Edelman, A. M., Frenguelli, B. G., & Hardie, D. G. (2005) · Cell Metabolism · doi:10.1016/j.cmet.2005.05.009 · Cited by 1,589
Self-citationThe specificities of protein kinase inhibitors: an update
BAIN, J., McLAUCHLAN, H., ELLIOTT, M., & COHEN, P. (2003) · Biochemical Journal · doi:10.1042/bj20021535 · Cited by 1,369 · cited 5×
“The substrates used for other protein kinases were described previously[1, 2 ].”
BackgroundMethodInfluentialSelf-citationMeijer, L., Borgne, A., Mulner, O., Chong, J. P. J., Blow, J. J., Inagaki, N., Inagaki, M., Delcros, J., & Moulinoux, J. (1997) · European Journal of Biochemistry · doi:10.1111/j.1432-1033.1997.t01-2-00527.x · Cited by 1,352
A chemical switch for inhibitor-sensitive alleles of any protein kinase
Bishop, A. C., Ubersax, J. A., Petsch, D. T., Matheos, D. P., Gray, N. S., Blethrow, J., Shimizu, E., Tsien, J. Z., Schultz, P. G., Rose, M. D., et al. (2000) · Nature · doi:10.1038/35030148 · Cited by 1,031
Blockade of the MAP kinase pathway suppresses growth of colon tumors in vivo
Sebolt-Leopold, J. S., Dudley, D. T., Herrera, R., Becelaere, K. V., Wiland, A., Gowan, R. C., Tecle, H., Barrett, S. D., Bridges, A., Przybranowski, S., et al. (1999) · Nature Medicine · doi:10.1038/10533 · Cited by 970
Harrington, E. A., Bebbington, D., Moore, J., Rasmussen, R. K., Ajose-Adeogun, A. O., Nakayama, T., Graham, J. A., Demur, C., Hercend, T., Diu-Hercend, A., et al. (2004) · Nature Medicine · doi:10.1038/nm1003 · Cited by 965
Rottlerin, a Novel Protein Kinase Inhibitor
Gschwendt, M., Muller, H. J., Kielbassa, K., Zang, R., Kittstein, W., Rincke, G., & Marks, F. (1994) · Biochemical and Biophysical Research Communications · doi:10.1006/bbrc.1994.1199 · Cited by 841
Inhibition of p38 MAP kinase by utilizing a novel allosteric binding site
Pargellis, C., Tong, L., Churchill, L., Cirillo, P. F., Gilmore, T., Graham, A. G., Grob, P. M., Hickey, E. R., Moss, N., Pav, S., et al. (2002) · Nature Structural Biology · doi:10.1038/nsb770 · Cited by 833
Exploiting Chemical Libraries, Structure, and Genomics in the Search for Kinase Inhibitors
Gray, N. S., Wodicka, L., Thunnissen, A.-M. W. H., Norman, T. C., Kwon, S., Espinoza, F. H., Morgan, D. O., Barnes, G., LeClerc, S., Meijer, L., et al. (1998) · Science · doi:10.1126/science.281.5376.533 · Cited by 808
GSK3 inhibitors: development and therapeutic potential
Cohen, P., & Goedert, M. (2004) · Nature Reviews Drug Discovery · doi:10.1038/nrd1415 · Cited by 790
Self-citationNFAT dysregulation by increased dosage of DSCR1 and DYRK1A on chromosome 21
Arron, J. R., Winslow, M. M., Polleri, A., Chang, C.-P., Wu, H., Gao, X., Neilson, J. R., Chen, L., Heit, J. J., Kim, S. K., et al. (2006) · Nature · doi:10.1038/nature04678 · Cited by 698
An essential part for Rho–associated kinase in the transcellular invasion of tumor cells
Itoh, K., Yoshioka, K., Akedo, H., Uehata, M., Ishizaki, T., & Narumiya, S. (1999) · Nature Medicine · doi:10.1038/5587 · Cited by 600
A dual PI3 kinase/mTOR inhibitor reveals emergent efficacy in glioma
Fan, Q.-W., Knight, Z. A., Goldenberg, D. D., Yu, W., Mostov, K. E., Stokoe, D., Shokat, K. M., & Weiss, W. A. (2006) · Cancer Cell · doi:10.1016/j.ccr.2006.03.029 · Cited by 585
SU6656, a Selective Src Family Kinase Inhibitor, Used To Probe Growth Factor Signaling
Blake, R. A., Broome, M. A., Liu, X., Wu, J., Gishizky, M., Sun, L., & Courtneidge, S. A. (2000) · Molecular and Cellular Biology · doi:10.1128/mcb.20.23.9018-9027.2000 · Cited by 584
Inhibition of drug-resistant mutants of ABL, KIT, and EGF receptor kinases
Carter, T. A., Wodicka, L. M., Shah, N. P., Velasco, A. M., Fabian, M. A., Treiber, D. K., Milanov, Z. V., Atteridge, C. E., Biggs, W. H., Edeen, P. T., et al. (2005) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0504952102 · Cited by 554
Bhat, R., Xue, Y., Berg, S., Hellberg, S., Ormö, M., Nilsson, Y., Radesäter, A.-C., Jerning, E., Markgren, P.-O., Borgegård, T., et al. (2003) · Journal of Biological Chemistry · doi:10.1074/jbc.m306268200 · Cited by 552
Activation of the Protein Kinase ERK5/BMK1 by Receptor Tyrosine Kinases
Kamakura, S., Moriguchi, T., & Nishida, E. (1999) · Journal of Biological Chemistry · doi:10.1074/jbc.274.37.26563 · Cited by 510
Structural Bioinformatics-Based Design of Selective, Irreversible Kinase Inhibitors
Cohen, M. S., Zhang, C., Shokat, K. M., & Taunton, J. (2005) · Science · doi:10.1126/science1108367 · Cited by 506
Exploring the specificity of the PI3K family inhibitor LY294002
Gharbi, S. I., Zvelebil, M. J., Shuttleworth, S. J., Hancox, T., Saghir, N., Timms, J. F., & Waterfield, M. D. (2007) · Biochemical Journal · doi:10.1042/bj20061489 · Cited by 462
Wiggin, G. R., Soloaga, A., Foster, J. M., Murray-Tait, V., Cohen, P., & Arthur, J. S. C. (2002) · Molecular and Cellular Biology · doi:10.1128/mcb.22.8.2871-2881.2002 · Cited by 445
Self-citationWortmannin, a microbial product inhibitor of myosin light chain kinase.
Nakanishi, S., Kakita, S., Takahashi, I., Kawahara, K., Tsukuda, E., Sano, T., Yamada, K., Yoshida, M., Kase, H., & Matsuda, Y. (1992) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(18)45857-7 · Cited by 429
Discovery of a novel Raf kinase inhibitor.
Lyons, J. F., Wilhelm, S., Hibner, B., & Bollag, G. (2001) · Endocrine-related cancer · doi:10.1677/erc.0.0080219 · Cited by 416
BARNETT, S. F., DEFEO-JONES, D., FU, S., HANCOCK, P. J., HASKELL, K. M., JONES, R. E., KAHANA, J. A., KRAL, A. M., LEANDER, K., LEE, L. L., et al. (2005) · Biochemical Journal · doi:10.1042/bj20041140 · Cited by 396
Altafaj, X. (2001) · Human Molecular Genetics · doi:10.1093/hmg/10.18.1915 · Cited by 396
Chien, Y., Kim, S., Bumeister, R., Loo, Y.-M., Kwon, S. W., Johnson, C. L., Balakireva, M. G., Romeo, Y., Kopelovich, L., Gale, M., et al. (2006) · Cell · doi:10.1016/j.cell.2006.08.034 · Cited by 368
Roscovitine Targets, Protein Kinases and Pyridoxal Kinase
Bach, S., Knockaert, M., Reinhardt, J., Lozach, O., Schmitt, S., Baratte, B., Koken, M., Coburn, S. P., Tang, L., Jiang, T., et al. (2005) · Journal of Biological Chemistry · doi:10.1074/jbc.m500806200 · Cited by 356
Pyrazole Urea-Based Inhibitors of p38 MAP Kinase: From Lead Compound to Clinical Candidate
Regan, J., Breitfelder, S., Cirillo, P., Gilmore, T., Graham, A. G., Hickey, E., Klaus, B., Madwed, J., Moriak, M., Moss, N., et al. (2002) · Journal of Medicinal Chemistry · doi:10.1021/jm020057r · Cited by 348
MURRAY, J. T., CAMPBELL, D. G., MORRICE, N., AULD, G. C., SHPIRO, N., MARQUEZ, R., PEGGIE, M., BAIN, J., BLOOMBERG, G. B., GRAHAMMER, F., et al. (2004) · Biochemical Journal · doi:10.1042/bj20041057 · Cited by 341
Self-citationAn efficient proteomics method to identify the cellular targets of protein kinase inhibitors
Godl, K., Wissing, J., Kurtenbach, A., Habenberger, P., Blencke, S., Gutbrod, H., Salassidis, K., Stein-Gerlach, M., Missio, A., Cotten, M., et al. (2003) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2535024100 · Cited by 336
Tamás, P., Hawley, S. A., Clarke, R. G., Mustard, K. J., Green, K., Hardie, D. G., & Cantrell, D. A. (2006) · The Journal of Experimental Medicine · doi:10.1084/jem.20052469 · Cited by 328
Chemical Genetic Analysis of the Time Course of Signal Transduction by JNK
Ventura, J.-J., Hübner, A., Zhang, C., Flavell, R. A., Shokat, K. M., & Davis, R. J. (2006) · Molecular Cell · doi:10.1016/j.molcel.2006.01.018 · Cited by 323
Eyers, P. A., Craxton, M., Morricel, N., Cohen, P., & Goedert, M. (1998) · Chemistry & Biology · doi:10.1016/s1074-5521(98)90170-3 · Cited by 310
Self-citationCallahan, J. F., Burgess, J. L., Fornwald, J. A., Gaster, L. M., Harling, J. D., Harrington, F. P., Heer, J., Kwon, C., Lehr, R., Mathur, A., et al. (2002) · Journal of Medicinal Chemistry · doi:10.1021/jm010493y · Cited by 308
BI-D1870 is a specific inhibitor of the p90 RSK (ribosomal S6 kinase) isoforms in vitro and in vivo
Sapkota, G. P., Cummings, L., Newell, F. S., Armstrong, C., Bain, J., Frodin, M., Grauert, M., Hoffmann, M., Schnapp, G., Steegmaier, M., et al. (2007) · Biochemical Journal · doi:10.1042/bj20061088 · Cited by 308
Self-citationBIRB796 Inhibits All p38 MAPK Isoforms in Vitro and in Vivo
Kuma, Y., Sabio, G., Bain, J., Shpiro, N., Márquez, R., & Cuenda, A. (2005) · Journal of Biological Chemistry · doi:10.1074/jbc.m414221200 · Cited by 304
Self-citationSmith, J. A., Poteet-Smith, C. E., Xu, Y., Errington, T. M., Hecht, S. M., & Lannigan, D. A. (2005) · Cancer Research · doi:10.1158/0008-5472.1027.65.3 · Cited by 284
Feedback control of the protein kinase TAK1 by SAPK2a/p38
Cheung, P. C. F. (2003) · The EMBO Journal · doi:10.1093/emboj/cdg552 · Cited by 278
The COOH Terminus of Rho-kinase Negatively Regulates Rho-kinase Activity
Amano, M., Chihara, K., Nakamura, N., Kaneko, T., Matsuura, Y., & Kaibuchi, K. (1999) · Journal of Biological Chemistry · doi:10.1074/jbc.274.45.32418 · Cited by 272
Paradoxical activation of Raf by a novel Raf inhibitor
Hall-Jackson, C. A., Eyers, P. A., Cohen, P., Goedert, M., Tom Boyle, F., Hewitt, N., Plant, H., & Hedge, P. (1999) · Chemistry & Biology · doi:10.1016/s1074-5521(99)80088-x · Cited by 265
Self-citationSun, L., Tran, N., Liang, C., Tang, F., Rice, A., Schreck, R., Waltz, K., Shawver, L. K., McMahon, G., & Tang, C. (1999) · Journal of Medicinal Chemistry · doi:10.1021/jm9904295 · Cited by 259
Structural basis for selective inhibition of Src family kinases by PP1
Liu, Y., Bishop, A., Witucki, L., Kraybill, B., Shimizu, E., Tsien, J., Ubersax, J., Blethrow, J., Morgan, D. O., & Shokat, K. M. (1999) · Chemistry & Biology · doi:10.1016/s1074-5521(99)80118-5 · Cited by 252
Effects of MAP kinase cascade inhibitors on the MKK5/ERK5 pathway
Mody, N., Leitch, J., Armstrong, C., Dixon, J., & Cohen, P. (2001) · FEBS Letters · doi:10.1016/s0014-5793(01)02651-5 · Cited by 250
Self-citationRena, G., Bain, J., Elliott, M., & Cohen, P. (2004) · EMBO reports · doi:10.1038/sj.embor.7400048 · Cited by 249
Self-citationKnauf, U., Tschopp, C., & Gram, H. (2001) · Molecular and Cellular Biology · doi:10.1128/mcb.21.16.5500-5511.2001 · Cited by 248
Potent and selective inhibitors of Akt kinases slow the progress of tumors in vivo
Luo, Y., Shoemaker, A. R., Liu, X., Woods, K. W., Thomas, S. A., de Jong, R., Han, E. K., Li, T., Stoll, V. S., Powlas, J. A., et al. (2005) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-05-0005 · Cited by 232
Gum, R. J., McLaughlin, M. M., Kumar, S., Wang, Z., Bower, M. J., Lee, J. C., Adams, J. L., Livi, G. P., Goldsmith, E. J., & Young, P. R. (1998) · Journal of Biological Chemistry · doi:10.1074/jbc.273.25.15605 · Cited by 229
Novel Small Molecule Inhibitors of 3-Phosphoinositide-dependent Kinase-1
Feldman, R. I., Wu, J. M., Polokoff, M. A., Kochanny, M. J., Dinter, H., Zhu, D., Biroc, S. L., Alicke, B., Bryant, J., Yuan, S., et al. (2005) · Journal of Biological Chemistry · doi:10.1074/jbc.m501367200 · Cited by 228
Liu, Y., Shreder, K. R., Gai, W., Corral, S., Ferris, D. K., & Rosenblum, J. S. (2005) · Chemistry & Biology · doi:10.1016/j.chembiol.2004.11.009 · Cited by 209
Transformation mediated by RhoA requires activity of ROCK kinases
Sahai, E., Ishizaki, T., Narumiya, S., & Treisman, R. (1999) · Current Biology · doi:10.1016/s0960-9822(99)80067-0 · Cited by 203
The Small Molecule Harmine Is an Antidiabetic Cell-Type-Specific Regulator of PPARγ Expression
Waki, H., Park, K. W., Mitro, N., Pei, L., Damoiseaux, R., Wilpitz, D. C., Reue, K., Saez, E., & Tontonoz, P. (2007) · Cell Metabolism · doi:10.1016/j.cmet.2007.03.010 · Cited by 202
Molecular mechanisms involved in the regulation of cytokine production by muramyl dipeptide
Windheim, M., Lang, C., Peggie, M., Plater, L. A., & Cohen, P. (2007) · Biochemical Journal · doi:10.1042/bj20061704 · Cited by 200
Self-citationLiverton, N. J., Butcher, J. W., Claiborne, C. F., Claremon, D. A., Libby, B. E., Nguyen, K. T., Pitzenberger, S. M., Selnick, H. G., Smith, G. R., Tebben, A., et al. (1999) · Journal of Medicinal Chemistry · doi:10.1021/jm9805236 · Cited by 196
Specific inhibition of cyclin-dependent kinases and cell proliferation by harmine
Song, Y., Kesuma, D., Wang, J., Deng, Y., Duan, J., Wang, J. H., & Qi, R. Z. (2004) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2004.03.019 · Cited by 180
JNK2 Is a Positive Regulator of the cJun Transcription Factor
Jaeschke, A., Karasarides, M., Ventura, J.-J., Ehrhardt, A., Zhang, C., Flavell, R. A., Shokat, K. M., & Davis, R. J. (2006) · Molecular Cell · doi:10.1016/j.molcel.2006.07.028 · Cited by 161
Zaru, R., Ronkina, N., Gaestel, M., Arthur, J. S. C., & Watts, C. K. W. (2007) · Nature Immunology · doi:10.1038/ni1517 · Cited by 160
Self-citationNiggli, V. (1999) · FEBS Letters · doi:10.1016/s0014-5793(99)00098-8 · Cited by 159
[29] Assay and expression of mitogen-activated protein kinase, MAP kinase kinase, and Raf
Alessi, D. R., Cohen, P., Ashworth, A., Cowley, S., Leevers, S. J., & Marshall, C. J. (1995) · Methods in Enzymology · doi:10.1016/s0076-6879(95)55031-3 · Cited by 158
Self-citationHypomorphic Mutation of PDK1 Suppresses Tumorigenesis in PTEN+/− Mice
Bayascas, J. R., Leslie, N. R., Parsons, R. E., Fleming, S., & Alessi, D. R. (2005) · Current Biology · doi:10.1016/j.cub.2005.08.066 · Cited by 158
Self-citationA clickable inhibitor reveals context-dependent autoactivation of p90 RSK
Cohen, M. S., Hadjivassiliou, H., & Taunton, J. (2007) · Nature Chemical Biology · doi:10.1038/nchembio859 · Cited by 156
Effect of SB 203580 on the activity of c-Raf in vitro and in vivo
Hall-Jackson, C. A., Goedert, M., Hedge, P., & Cohen, P. (1999) · Oncogene · doi:10.1038/sj.onc.1202603 · Cited by 151
Self-citationGaillard, P., Jeanclaude-Etter, I., Ardissone, V., Arkinstall, S., Cambet, Y., Camps, M., Chabert, C., Church, D. J., Cirillo, R., Gretener, D., et al. (2005) · Journal of Medicinal Chemistry · doi:10.1021/jm0310986 · Cited by 129
Characterization of a Protein Kinase B Inhibitor In Vitro and in Insulin-Treated Liver Cells
Logie, L., Ruiz‐Alcaraz, A. J., Keane, M. P., Woods, Y. L., Bain, J., Márquez, R., Alessi, D. R., & Sutherland, C. D. (2007) · Diabetes · doi:10.2337/db07-0343 · Cited by 120
Self-citationVX-680 Inhibits Aurora A and Aurora B Kinase Activity in Human Cells
Tyler, R. K., Shpiro, N., Márquez, R., & Eyers, P. A. (2007) · Cell Cycle · doi:10.4161/cc.6.22.4940 · Cited by 118
Self-citationEyers, P. A., van den IJssel, P., Quinlan, R. A., Goedert, M., & Cohen, P. (1999) · FEBS Letters · doi:10.1016/s0014-5793(99)00552-9 · Cited by 113
Self-citationGodl, K., Gruß, O. J., Eickhoff, J., Wissing, J. B., Blencke, S., Weber, M., Degen, H., Brehmer, D., Őrfi, L., Horváth, Z., et al. (2005) · Cancer Research · doi:10.1158/0008-5472.can-05-0574 · Cited by 105
Korherr, C., Gille, H., Schäfer, R., Koenig‐Hoffmann, K., Dixelius, J., Egland, K. A., Pastan, I. H., & Brinkmann, U. (2006) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0511319103 · Cited by 99
Shaw, M., & Cohen, P. (1999) · FEBS Letters · doi:10.1016/s0014-5793(99)01434-9 · Cited by 87
Self-citationFryer, L. G. D., Patel, A. P., & Carling, D. (2002) · FEBS Letters · doi:10.1016/s0014-5793(02)03501-9 · Cited by 77
Cho, J., Melnick, M., Solidakis, G. P., & Tsichlis, P. N. (2005) · Journal of Biological Chemistry · doi:10.1074/jbc.m413554200 · Cited by 53
Cited by
The ground state of embryonic stem cell self-renewal
Ying, Q.-L., Wray, J., Nichols, J., Batlle-Morera, L., Doble, B., Woodgett, J., Cohen, P., & Smith, A. (2008) · Nature · doi:10.1038/nature06968 · Cited by 3,442
Self-citationWatterson, K. R., Bestow, D., Gallagher, J., Hamilton, D. L., Ashford, F. B., Meakin, P. J., & Ashford, M. L. J. (2013) · Neurosignals · doi:10.1159/000334144 · Cited by 3,389
Activation and function of the MAPKs and their substrates, the MAPK-activated protein kinases
Cargnello, M., & Roux, P. P. (2011) · Microbiology and Molecular Biology Reviews · doi:10.1128/mmbr.00031-10 · Cited by 3,274
Targeting cancer with small molecule kinase inhibitors
Zhang, J., Yang, P. L., & Gray, N. S. (2009) · Nature Reviews Cancer · doi:10.1038/nrc2559 · Cited by 2,576
Mammalian MAPK Signal Transduction Pathways Activated by Stress and Inflammation: A 10-Year Update
Kyriakis, J. M., & Avruch, J. (2012) · Physiological Reviews · doi:10.1152/physrev.00028.2011 · Cited by 1,466
Metadata
- Authors
- Bain, J., Plater, L., Elliott, M., Shpiro, N., Hastie, C. J., Mclauchlan, H., Klevernic, I., Arthur, J. S. C., Alessi, D. R., & Cohen, P.
- Venue
- Biochemical Journal
- Publisher
- Portland Press Ltd.
- Published
- 2007-11-28
- Volume
- 408
- Issue
- 3
- Pages
- 297-315
- ISSN
- 0264-6021 (ISSN-L)
- 1470-8728
- OpenAlex
- W2046822015
- Cited by
- 2,520
- References
- 82
- FWCI
- 64.06
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.